EHA 2023 Press Briefing, Friday June 9
- S102 (the abstract was presented at ASCO). LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
- S104. DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
- S136. ANALYSIS OF FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY
- S145. VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
- S270. TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
- LB2711. BMT-CTN 1506 (MORPHO): A RANDOMIZED TRIAL OF THE FLT3 INHIBITOR GILTERITINIB AS POST-TRANSPLANT MAINTENANCE FOR FLT3-ITD AML
- LB2710. TARGETED THERAPY OF UNCONTROLLED ERYTHROCYTOSIS IN POLYCYTHEMIA VERA WITH THE HEPCIDIN MIMETIC, RUSFERTIDE: - BLINDED RANDOMIZED WITHDRAWAL RESULTS OF THE REVIVE STUDY
Dr Matteo Giovanni Della Porta, Humanitas University and Research Hospital, Rozzano, Milan, Italy [remote presentation]
Dr Sascha Haubner, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
Dr Maria Teresa Vosso, Tor Vergata University, Rome, Italy
Dr Othman Al-Sawaf, University Hospital of Cologne, Cologne, Germany
Dr Franco Locatelli, Catholic University of the Sacred Heart, Bambino Gesù Children’s Hospital, Rome, Italy
Dr Mark J Levis, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Bal�more, MD, United States of America
Dr Ronald Hoffman, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America